Mini-COMET: Individual-level treatment responses in infantile-onset Pompe disease participants receiving avalglucosidase alfa or alglucosidase alfa who previously received alglucosidase alfa
Priya S. Kishnani(Duke Medical Center), David Kronn(New York Medical College), Satoko Kumada(Tokyo Metropolitan Neurological Hospital), Kristina An Haack(Sanofi (France)), Alexander Broomfield(St Mary's Hospital), Hirotaka Ohki(Tokyo Metropolitan Children's Medical Center), Si Houn Hahn(University of Washington), Anaïs Brassier(Hôpital Necker-Enfants Malades), Xianzhang Meng(Jilin Agricultural University), Judith Johnson(Sanofi (United States)), Samia Pichard, Yin‐Hsiu Chien(National Taiwan University Hospital), François Labarthe(Université de Tours), James Davison(Great Ormond Street Hospital for Children NHS Foundation Trust)
Cited by 1
Related Papers
Biparental Inheritance of Mitochondrial DNA in Humans
|Proceedings of the National Academy of Sciences|2018|451
Glycogen Storage Disease Type III diagnosis and management guidelines
|Genetics in Medicine|2010|305
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
|Genetics in Medicine|2009|292
Schwannomatosis
|Neurology|1996|244
Targeted long-read sequencing identifies missing disease-causing variation
|The American Journal of Human Genetics|2021|239